Clinical Trial Update: A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Xifaxan to vancomycin for treatment of Clostridium difficile–associated diarrhea has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection
• Diarrhea

Drugs mentioned

• Vancomycin (vancomycin)
• XIFAXAN (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Clostridium Infections, Diarrhea | Phase 3 | Status: COMPLETED | Results posted: 2019-10-01